Lung cancer trials in Spain

In Spain 273 Also abroad 2733

273 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela, Valencia
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
Phase 1/2Taking people
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Madrid
Age
18 years and over
People
240 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07325136 · EU 2025-524090-16-00
No phaseTaking people
Comparison of Biportal Versus Multiportal Robotic Approaches for Pulmonary Resection in NSCLC
Where
L'Hospitalet de Llobregat
Age
18 years and over
People
80
Run by
Carlos Déniz
See details and how to joinNCT07818135
Phase 1/2Taking people
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
250 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06657222 · EU 2025-522517-35-00
Phase 1Taking people
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Where
Barcelona, Madrid, Málaga, Seville, Valencia
Age
18 years and over
People
383 worldwide
Run by
Iambic Therapeutics, Inc
See details and how to joinNCT06253871
Phase 2Taking people
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
Where
Alicante, Barakaldo, Barcelona, Elche, Girona, León, Lugo, Madrid, Murcia, Oviedo, Pamplona, Reus, Sabadell, Santiago de Compostela, Valencia
Age
18 years and over
People
20 worldwide
Run by
MedSIR
See details and how to joinNCT06315010 · EU 2023-508112-35-00
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Barcelona, Girona, Madrid, Marbella, Santiago De Compostela, Valencia
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
Phase 1Taking people
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Where
Barcelona, Horta-Guinardó, Madrid
Age
18 years and over
People
350 worldwide
Run by
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06343402
Phase 1Taking people
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Where
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia
Age
18 years and over
People
400 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT04913285
Phase 1/2Taking people
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Where
Barcelona, Logroño, Madrid
Age
18 years and over
People
171 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06567015 · EU 2023-510203-21-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
Where
A Coruña, Badalona, Barcelona, Córdoba, Girona, Jaén, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Málaga, Sevilla, Valencia
Age
18 years and over
People
355 worldwide
Run by
Gilead Sciences Inc.
See details and how to join2024-515884-69-00 · EU 2024-515884-69-00
Phase 2Taking people
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
Where
A Coruña, Badalona, Madrid
Age
18 years and over
People
36 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01
Phase 1/2Taking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Barcelona, Madrid
Age
18 years to 100 years
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
Phase 3Taking people
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Where
A Coruña, Barcelona, Granada, Madrid, Majadahonda, Valencia
Age
18 years and over
People
582 worldwide
Run by
AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00
Phase 1/2Taking people
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Where
Barcelona, Córdoba, Málaga, Sevilla, Torrejón de Ardoz, Valencia
Age
18 years and over
People
594 worldwide
Run by
BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01
Phase 1Taking people
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Where
Barcelona, Madrid, Málaga, Valencia
Age
18 years to 99 years
People
160 worldwide
Run by
Amgen
See details and how to joinNCT07531095 · EU 2025-522888-15-00
Phase 1Taking people
A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of VVD130037, in Participants With Advanced Solid Tumors
Where
Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
65
Run by
Vividion Therapeutics Inc.
See details and how to joinNCT05954312 · EU 2023-506199-28-00
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Barcelona, Málaga, Oviedo, Palma, Valencia
Age
18 years and over
People
36 worldwide
Run by
Arrivent Biopharma Inc.
See details and how to join2025-522151-26-00 · EU 2025-522151-26-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Badalona, Barcelona, Madrid, Málaga, Pamplona
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 1Taking people
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Where
Sevilla
People
7 worldwide
Run by
USWM Ct LLC
See details and how to join2024-513033-21-00 · EU 2024-513033-21-00
Phase 2Not yet taking people in Spain
A trial to learn how safe newer immunotherapy drugs are and how well they work with or without other anti-cancer drugs in adults with advanced, unresectable non-small cell lung cancer
Where
Barcelona, Madrid, Málaga, Vigo
Age
18 years and over
People
11 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523599-21-00 · EU 2025-523599-21-00
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Barcelona, Madrid, Majadahonda, Málaga, Valencia
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00
Phase 1/2Taking people
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
366 worldwide
Run by
Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01
Phase 4Taking people
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
Where
Logroño, Madrid
Age
18 years and over
People
12
Run by
Rigel Pharmaceuticals
See details and how to joinNCT07704658
Phase 3Taking people
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Where
Barcelona, Córdoba, Jaén, Jerez de la Frontera, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla
Age
18 years and over
People
540 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00